Dr Katherin M. Duthie joins Ethics Talk to discuss her article, coauthored with Dr Kathryn A. Dong: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?”
Physicians need to inform parents about the limited effectiveness of growth hormone therapy in satisfying the treatment goals of children with idiopathic short stature.
A physician's role in controlling the abuse of performance-enhancing drugs includes educating patients about the harms associated with these drugs and encouraging them to adopt safe and appropriate training programs.
When patients and physicians disagree on the use of genetic engineering technology, physicians must act in accordance with professional ethics and society's guidelines.
Although parents may someday have the ability to enhance the complex physical and mental traits of their offspring, such genetic enhancements raise a number of difficult ethical questions.